Biocept Stock Price, News & Analysis (NASDAQ:BIOC)

$0.30 -0.01 (-2.59 %)
(As of 02/18/2018 05:18 AM ET)
Previous Close$0.30
Today's Range$0.30 - $0.32
52-Week Range$0.26 - $2.75
Volume703,698 shs
Average Volume3.05 million shs
Market Capitalization$19.11 million
P/E RatioN/A
Dividend YieldN/A
Beta1.98

About Biocept (NASDAQ:BIOC)

Biocept logoBiocept, Inc. is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company's Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample. The ctDNA technology enables mutation detection and is applicable to nucleic acid from CTCs or other sample types, such as blood plasma. The Company commercializes its Target-Selector assays for a range of solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, colorectal cancer, prostate cancer and melanoma.

Receive BIOC News and Ratings via Email

Sign-up to receive the latest news and ratings for BIOC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Diagnostic & Testing Substances
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BIOC
CUSIPN/A
Phone858-320-8200

Debt

Debt-to-Equity Ratio0.24%
Current Ratio1.41%
Quick Ratio1.27%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$3.22 million
Price / Sales5.94
Cash FlowN/A
Price / CashN/A
Book Value$0.04 per share
Price / Book7.53

Profitability

Trailing EPS($0.89)
Net Income$-18,390,000.00
Net Margins-375.28%
Return on Equity-359.21%
Return on Assets-157.08%

Miscellaneous

Employees70
Outstanding Shares63,590,000

Biocept (NASDAQ:BIOC) Frequently Asked Questions

What is Biocept's stock symbol?

Biocept trades on the NASDAQ under the ticker symbol "BIOC."

How were Biocept's earnings last quarter?

Biocept Inc (NASDAQ:BIOC) released its quarterly earnings data on Tuesday, August, 2nd. The medical research company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.02. The medical research company had revenue of $0.66 million for the quarter, compared to analysts' expectations of $0.37 million. Biocept had a negative return on equity of 359.21% and a negative net margin of 375.28%. View Biocept's Earnings History.

When will Biocept make its next earnings announcement?

Biocept is scheduled to release their next quarterly earnings announcement on Monday, March, 5th 2018. View Earnings Estimates for Biocept.

Where is Biocept's stock going? Where will Biocept's stock price be in 2018?

3 brokerages have issued 12-month price objectives for Biocept's stock. Their predictions range from $1.50 to $3.00. On average, they expect Biocept's share price to reach $2.25 in the next twelve months. View Analyst Ratings for Biocept.

Who are some of Biocept's key competitors?

Who are Biocept's key executives?

Biocept's management team includes the folowing people:

  • Michael W. Nall, President, Chief Executive Officer, Director (Age 53)
  • Timothy C. Kennedy, Chief Financial Officer and Senior Vice President of Operations
  • Lyle J. Arnold Ph. D., Senior Vice President - Research & Development, Chief Scientific Officer (Age 69)
  • Veena Singh M.D., Senior Vice President, Senior Medical Director (Age 41)
  • Michael Terry, Senior Vice President - Commercial Operations
  • Raaj Trivedi, Vice President - Commercial Operations (Age 43)
  • David S. Moskowitz, Vice President - Strategy and Corporate Communications (Age 53)
  • David F. Hale, Non-Executive Chairman of the Board (Age 67)
  • Marsha A. Chandler Ph.D., Independent Director (Age 71)
  • Bruce E. Gerhardt CPA, Independent Director (Age 65)

Who owns Biocept stock?

Biocept's stock is owned by a variety of of retail and institutional investors. Top institutional investors include SABBY MANAGEMENT, LLC (9.20%), SABBY MANAGEMENT, LLC (9.20%) and Sabby Management LLC (1.51%). Company insiders that own Biocept stock include Bruce Gerhardt, Claire Reiss, David F Hale, Ivor Royston, Lyle J Arnold and Timothy Kennedy. View Institutional Ownership Trends for Biocept.

Who bought Biocept stock? Who is buying Biocept stock?

Biocept's stock was bought by a variety of institutional investors in the last quarter, including Sabby Management LLC. Company insiders that have bought Biocept stock in the last two years include Bruce Gerhardt, Claire Reiss, David F Hale, Ivor Royston, Lyle J Arnold and Timothy Kennedy. View Insider Buying and Selling for Biocept.

How do I buy Biocept stock?

Shares of Biocept can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Biocept's stock price today?

One share of Biocept stock can currently be purchased for approximately $0.30.

How big of a company is Biocept?

Biocept has a market capitalization of $19.11 million and generates $3.22 million in revenue each year. The medical research company earns $-18,390,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis. Biocept employs 70 workers across the globe.

How can I contact Biocept?

Biocept's mailing address is 5810 NANCY RIDGE DR, SAN DIEGO CA, 92121. The medical research company can be reached via phone at 858-320-8200 or via email at [email protected]


MarketBeat Community Rating for Biocept (BIOC)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  155 (Vote Outperform)
Underperform Votes:  160 (Vote Underperform)
Total Votes:  315
MarketBeat's community ratings are surveys of what our community members think about Biocept and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Biocept (NASDAQ:BIOC) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $2.25$2.25$2.25$2.50
Price Target Upside: 251.56% upside251.56% upside251.56% upside78.57% upside

Biocept (NASDAQ:BIOC) Consensus Price Target History

Price Target History for Biocept (NASDAQ:BIOC)

Biocept (NASDAQ:BIOC) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/14/2017Chardan CapitalReiterated RatingBuy -> Buy$2.50 -> $1.50N/AView Rating Details
8/3/2017Westpark CapitalReiterated RatingOutperformLowView Rating Details
3/13/2017Roth CapitalReiterated RatingBuy$1.60 -> $3.00LowView Rating Details
11/10/2016Feltl & Co.UpgradeHold -> Buy$2.00N/AView Rating Details
8/31/2016Rodman & RenshawSet Price TargetBuy$2.50N/AView Rating Details
(Data available from 2/18/2016 forward)

Earnings

Biocept (NASDAQ:BIOC) Earnings History and Estimates Chart

Earnings by Quarter for Biocept (NASDAQ:BIOC)

Biocept (NASDAQ BIOC) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/5/2018N/AView Earnings Details
11/9/2017Q3 2017($0.19)($0.20)$1.39 million$1.11 millionViewN/AView Earnings Details
8/10/2017Q2 2017($0.20)($0.21)$1.23 million$1.28 millionViewN/AView Earnings Details
5/11/2017Q1 2017($0.22)($0.21)$1.32 million$1.68 millionViewN/AView Earnings Details
3/7/2017Q4 2016($0.34)($0.27)$1.26 million$1.29 millionViewListenView Earnings Details
11/9/2016Q316($0.57)($0.57)$0.76 million$1.05 millionViewListenView Earnings Details
8/2/2016Q216($0.22)($0.20)$0.37 million$0.66 millionViewN/AView Earnings Details
5/12/2016Q116($0.23)($0.25)$0.48 million$0.22 millionViewListenView Earnings Details
3/9/2016Q415($0.26)($0.24)$76.00 million$218.00 millionViewN/AView Earnings Details
11/5/2015Q315($0.22)($0.24)$0.78 million$0.17 millionViewN/AView Earnings Details
8/10/2015Q215($0.23)($0.22)$19.25 million$76.77 millionViewListenView Earnings Details
5/12/2015Q115($0.61)($0.37)$0.30 million$0.15 millionViewListenView Earnings Details
3/9/2015Q414($0.88)($0.87)$0.30 million$0.08 millionViewN/AView Earnings Details
11/13/2014Q3 2014($0.82)($0.87)$0.40 million$0.01 millionViewN/AView Earnings Details
8/14/2014Q2 2014($0.67)($0.67)$0.10 million$0.02 millionViewN/AView Earnings Details
5/14/2014Q1 2014($5.88)$0.03 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Biocept (NASDAQ:BIOC) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.76 EPS
Next Year EPS Consensus Estimate: $-0.51 EPS

Dividends

Dividend History for Biocept (NASDAQ:BIOC)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Biocept (NASDAQ BIOC) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.70%
Institutional Ownership Percentage: 3.71%
Insider Trades by Quarter for Biocept (NASDAQ:BIOC)
Institutional Ownership by Quarter for Biocept (NASDAQ:BIOC)

Biocept (NASDAQ BIOC) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/19/2016Claire ReissMajor ShareholderBuy227,272$1.10$249,999.20View SEC Filing  
10/19/2016David F. HaleDirectorBuy90,909$1.10$99,999.90View SEC Filing  
10/19/2016Lyle J. ArnoldSVPBuy45,000$1.10$49,500.00View SEC Filing  
10/19/2016Timothy KennedyCFOBuy36,363$1.10$39,999.30View SEC Filing  
5/4/2016Bruce GerhardtDirectorBuy25,000$1.00$25,000.0058,985View SEC Filing  
5/4/2016Claire ReissMajor ShareholderBuy614,273$1.00$614,273.00View SEC Filing  
2/13/2015David F HaleChairmanBuy40,000$1.25$50,000.00View SEC Filing  
2/13/2015Marsha Alpert ChandlerDirectorBuy2,000$1.25$2,500.00View SEC Filing  
2/13/2015Michael W NallCEOBuy12,000$1.25$15,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Biocept (NASDAQ BIOC) News Headlines

Source:
DateHeadline
Biocept Receives Additional Patent Issuances in Three Major International Territories for its Target Selector PlatformBiocept Receives Additional Patent Issuances in Three Major International Territories for its Target Selector Platform
finance.yahoo.com - February 5 at 8:58 AM
Dawson James Securities Announces Closing of Approximately $14.78M Public Offering for Biocept, Inc.Dawson James Securities Announces Closing of Approximately $14.78M Public Offering for Biocept, Inc.
finance.yahoo.com - February 1 at 9:10 AM
Biocept Comments on Updated Consensus Medical Guidelines Recommending Liquid Biopsy for Profiling of Tumor Biomarkers to Assist with the Treatment of Patients with Lung CancerBiocept Comments on Updated Consensus Medical Guidelines Recommending Liquid Biopsy for Profiling of Tumor Biomarkers to Assist with the Treatment of Patients with Lung Cancer
finance.yahoo.com - January 30 at 8:47 AM
Technical Perspectives on Medical Research Stocks -- Accelerate Diagnostics, Biocept, Exact Sciences, and HTG Molecular DiagnosticsTechnical Perspectives on Medical Research Stocks -- Accelerate Diagnostics, Biocept, Exact Sciences, and HTG Molecular Diagnostics
www.bizjournals.com - January 29 at 9:10 AM
Biocept Announces Pricing of $15.0 Million Public Offering of 33333333 Shares of Common Stock and Warrants to ... - PR Newswire (press release)Biocept Announces Pricing of $15.0 Million Public Offering of 33333333 Shares of Common Stock and Warrants to ... - PR Newswire (press release)
www.prnewswire.com - January 27 at 3:42 PM
Biocept Inc (BIOC) Dilutes Shareholders a Second Time in Two MonthsBiocept Inc (BIOC) Dilutes Shareholders a Second Time in Two Months
finance.yahoo.com - January 26 at 3:39 PM
BRIEF-Biocept Prices $15 Million Public Offering Of 33.3 Mln Shares and WarrantsBRIEF-Biocept Prices $15 Million Public Offering Of 33.3 Mln Shares and Warrants
www.reuters.com - January 26 at 8:43 AM
Biocept Announces Pricing of $15.0 Million Public Offering of 33,333,333 Shares of Common Stock and Warrants to Purchase 33,333,333 Shares of Common StockBiocept Announces Pricing of $15.0 Million Public Offering of 33,333,333 Shares of Common Stock and Warrants to Purchase 33,333,333 Shares of Common Stock
finance.yahoo.com - January 26 at 8:43 AM
Zacks Investment Research Lowers Biocept (BIOC) to HoldZacks Investment Research Lowers Biocept (BIOC) to Hold
www.americanbankingnews.com - January 18 at 6:10 PM
Scientists seek super-shot for flu 100 years after pandemicScientists seek super-shot for flu 100 years after pandemic
finance.yahoo.com - January 17 at 3:38 PM
Biocept (BIOC) Rating Increased to Buy at Zacks Investment ResearchBiocept (BIOC) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - January 15 at 7:28 PM
Biocept Study Shows Incorporation of Thermo Fisher QuantStudio 5 PCR Instrument into Target Selector Platform Improves Sensitivity and Specificity in Detection of Lung Cancer BiomarkersBiocept Study Shows Incorporation of Thermo Fisher QuantStudio 5 PCR Instrument into Target Selector Platform Improves Sensitivity and Specificity in Detection of Lung Cancer Biomarkers
finance.yahoo.com - January 9 at 11:10 AM
Biocept Obtains Patent in Australia for its Molecular Biomarker ... - PR Newswire (press release)Biocept Obtains Patent in Australia for its Molecular Biomarker ... - PR Newswire (press release)
www.prnewswire.com - January 5 at 11:42 AM
Biocept Obtains Patent in Australia for its Molecular Biomarker Technology For the Detection of Cancer-Associated Mutations in Blood, Tissue, and Other Biological SourcesBiocept Obtains Patent in Australia for its Molecular Biomarker Technology For the Detection of Cancer-Associated Mutations in Blood, Tissue, and Other Biological Sources
finance.yahoo.com - January 4 at 11:14 AM
ETFs with exposure to Biocept, Inc. : December 28, 2017ETFs with exposure to Biocept, Inc. : December 28, 2017
finance.yahoo.com - December 28 at 5:00 PM
Exact Sciences Corporation (EXAS)Exact Sciences Corporation (EXAS)
finance.yahoo.com - December 19 at 3:38 PM
GlaxoSmithKline (Egypt): Strong price momentum but will it sustain?GlaxoSmithKline (Egypt): Strong price momentum but will it sustain?
finance.yahoo.com - December 19 at 3:38 PM
Biocept Signs In-Network Provider Agreement with Wellmark Blue Cross Blue Shield Expanding Coverage for its ... - PR Newswire (press release)Biocept Signs In-Network Provider Agreement with Wellmark Blue Cross Blue Shield Expanding Coverage for its ... - PR Newswire (press release)
www.prnewswire.com - December 18 at 11:55 AM
Biocept Signs In-Network Provider Agreement with Wellmark Blue Cross Blue Shield Expanding Coverage for its Target Selector Platform in Iowa and South DakotaBiocept Signs In-Network Provider Agreement with Wellmark Blue Cross Blue Shield Expanding Coverage for its Target Selector Platform in Iowa and South Dakota
finance.yahoo.com - December 18 at 11:55 AM
ETFs with exposure to Biocept, Inc. : December 11, 2017ETFs with exposure to Biocept, Inc. : December 11, 2017
finance.yahoo.com - December 11 at 3:37 PM
Mid-Day Market Update: Crude Oil Down 1.5%; AeroVironment Shares Climb After Strong Q2 ResultsMid-Day Market Update: Crude Oil Down 1.5%; AeroVironment Shares Climb After Strong Q2 Results
www.nasdaq.com - December 6 at 3:38 PM
BRIEF-Sabby Management LLC Reports A 9.20 Pct Passive Stake In BioceptBRIEF-Sabby Management LLC Reports A 9.20 Pct Passive Stake In Biocept
www.reuters.com - December 6 at 3:38 PM
What Spooked Biocept Inc (BIOC) Investors TodayWhat Spooked Biocept Inc (BIOC) Investors Today
finance.yahoo.com - December 6 at 3:38 PM
What Spooked Biocept Inc (BIOC) Investors TodayWhat Spooked Biocept Inc (BIOC) Investors Today
finance.yahoo.com - December 6 at 3:38 PM
Global Liquid Biopsy Market, Analysis and Forecast, 2017-2025Global Liquid Biopsy Market, Analysis and Forecast, 2017-2025
finance.yahoo.com - December 6 at 8:47 AM
Today’s Research Reports on Stocks to Watch: Neuralstem, Inc. and Biocept Inc.Today’s Research Reports on Stocks to Watch: Neuralstem, Inc. and Biocept Inc.
finance.yahoo.com - December 6 at 8:47 AM
Biocept Announces Pricing of Public Offering of up to 4,925,936 Shares of Common StockBiocept Announces Pricing of Public Offering of up to 4,925,936 Shares of Common Stock
finance.yahoo.com - December 6 at 8:47 AM
Biocept (BIOC) Secures Patent on Target Selector Oncogene ... - StreetInsider.comBiocept (BIOC) Secures Patent on Target Selector Oncogene ... - StreetInsider.com
www.streetinsider.com - December 5 at 6:02 PM
Biocept Inc Shares Skyrocket on Surprise Patent VictoryBiocept Inc Shares Skyrocket on Surprise Patent Victory
finance.yahoo.com - December 5 at 6:02 PM
Biocept (BIOC) Secures Patent on Target Selector Oncogene Mutation Enrichment & Detection Liquid Biopsy ctDNA PlatformBiocept (BIOC) Secures Patent on Target Selector Oncogene Mutation Enrichment & Detection Liquid Biopsy ctDNA Platform
www.streetinsider.com - December 5 at 1:02 PM
First U.S. Patent Issued for Biocepts Target Selector Oncogene Mutation Enrichment and Detection Liquid Biopsy ctDNA PlatformFirst U.S. Patent Issued for Biocept's Target Selector Oncogene Mutation Enrichment and Detection Liquid Biopsy ctDNA Platform
finance.yahoo.com - December 5 at 1:02 PM
Comparing Biocept (BIOC) and IRIS International (IRIS)Comparing Biocept (BIOC) and IRIS International (IRIS)
www.americanbankingnews.com - December 2 at 9:38 AM
Biocept and UC San Diego Medical Center Announce Clinical Study Collaboration to Demonstrate Utility of Biocepts ... - PR Newswire (press release)Biocept and UC San Diego Medical Center Announce Clinical Study Collaboration to Demonstrate Utility of Biocept's ... - PR Newswire (press release)
www.prnewswire.com - November 30 at 3:37 PM
ETFs with exposure to Biocept, Inc. : November 29, 2017ETFs with exposure to Biocept, Inc. : November 29, 2017
finance.yahoo.com - November 29 at 11:25 AM
Biocept, Inc. :BIOC-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017Biocept, Inc. :BIOC-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
finance.yahoo.com - November 29 at 11:25 AM
Biocept and UC San Diego Medical Center Announce Clinical Study Collaboration to Demonstrate Utility of Biocepts Liquid Biopsy Test in ImmunotherapyBiocept and UC San Diego Medical Center Announce Clinical Study Collaboration to Demonstrate Utility of Biocept's Liquid Biopsy Test in Immunotherapy
finance.yahoo.com - November 28 at 3:37 PM
Financial Contrast: Biocept (BIOC) versus IRIS International (IRIS)Financial Contrast: Biocept (BIOC) versus IRIS International (IRIS)
www.americanbankingnews.com - November 23 at 5:46 PM
Biocept, Inc. (BIOC) Rating Increased to Hold at Zacks Investment ResearchBiocept, Inc. (BIOC) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - November 22 at 5:10 PM
Lab-Developed Tests Fill Important Gap in Oncology Testing: Kalorama ReportLab-Developed Tests Fill Important Gap in Oncology Testing: Kalorama Report
www.bizjournals.com - November 20 at 8:23 PM
Zacks Investment Research Lowers Biocept, Inc. (BIOC) to SellZacks Investment Research Lowers Biocept, Inc. (BIOC) to Sell
www.americanbankingnews.com - November 15 at 5:06 PM
Contrasting Biocept (BIOC) & IRIS International (IRIS)Contrasting Biocept (BIOC) & IRIS International (IRIS)
www.americanbankingnews.com - November 14 at 1:50 PM
Biocept, Inc. (BIOC) Given New $1.50 Price Target at Chardan CapitalBiocept, Inc. (BIOC) Given New $1.50 Price Target at Chardan Capital
www.americanbankingnews.com - November 14 at 8:46 AM
ETFs with exposure to Biocept, Inc. : November 13, 2017ETFs with exposure to Biocept, Inc. : November 13, 2017
finance.yahoo.com - November 14 at 1:00 AM
Reviewing Biocept (BIOC) & IRIS International (IRIS)Reviewing Biocept (BIOC) & IRIS International (IRIS)
www.americanbankingnews.com - November 11 at 7:16 PM
Biocept, Inc. to Host Earnings CallBiocept, Inc. to Host Earnings Call
finance.yahoo.com - November 9 at 5:42 PM
Biocept Reports Third Quarter 2017 Financial ResultsBiocept Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 9 at 5:42 PM
Biocept, Inc. (BIOC) Receives Consensus Recommendation of "Hold" from AnalystsBiocept, Inc. (BIOC) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - November 6 at 1:18 AM
Biocept to Release Third Quarter Financial Results and Host ... - PR Newswire (press release)Biocept to Release Third Quarter Financial Results and Host ... - PR Newswire (press release)
www.prnewswire.com - November 3 at 8:33 AM
Biocept to Release Third Quarter Financial Results and Host Investor Conference Call on November 9, 2017Biocept to Release Third Quarter Financial Results and Host Investor Conference Call on November 9, 2017
finance.yahoo.com - November 2 at 5:13 PM
ETFs with exposure to Biocept, Inc. : November 2, 2017ETFs with exposure to Biocept, Inc. : November 2, 2017
finance.yahoo.com - November 2 at 5:13 PM

SEC Filings

Biocept (NASDAQ:BIOC) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Biocept (NASDAQ:BIOC) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Biocept (NASDAQ BIOC) Stock Chart for Sunday, February, 18, 2018

Loading chart…

This page was last updated on 2/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.